Replimune Group, Inc. — FY2024 Form 10-K
Reporting period: Fiscal year ended March 31, 2024 (not calendar-year 2023 Q4). Filed May 16, 2024. Replimune is a clinical-stage biotechnology company developing oncolytic immunotherapies; it has no approved products and reported no product revenue.
Financial performance and position
| Metric | FY2024 | FY2023 | Change |
|---|---|---|---|
| Revenue from product sales | None | None | Pre-commercial |
| Research and development expense | $175.0 million | $126.5 million | Up 38% |
| Selling, general and administrative expense | $59.8 million | $50.6 million | Up 18% |
| Total operating expenses / operating loss | $234.8 million | $177.1 million | Up 33% |
| Net loss | $215.8 million | $174.3 million | Loss increased 24% |
| Net loss per share, basic and diluted | $3.24 | $2.99 | Loss per share increased |
| Net cash used in operating activities | $185.5 million | $128.1 million | Cash use increased |
Higher R&D reflected clinical-trial activity, patient enrollment, BLA preparation and increased personnel costs. Higher investment income and favorable foreign-exchange movements partly offset the larger operating loss. The filing does not provide revenue-based margins because the company has no product sales.
At March 31, 2024, cash and cash equivalents were $74.5 million and short-term investments were $346.2 million, totaling $420.7 million, versus $583.4 million a year earlier. Total current assets were $433.7 million and current liabilities were $40.4 million. Long-term debt, net of discount, was $44.8 million; the stated principal loan balance was $45.7 million. Lease liabilities totaled $31.1 million on a present-value basis, with $52.9 million of undiscounted future lease payments.
Operating cash outflow was $185.5 million. Investing activities provided $97.2 million, principally from net sales and maturities of short-term investments; financing activities provided $16.3 million, chiefly from a $15.0 million Hercules loan draw. Management’s current operating plan estimates existing cash and investments fund operations into the second half of calendar 2026. The filing also states that resources are sufficient for at least 12 months from issuance of the financial statements; both estimates depend on assumptions and clinical-development spending.
Material changes and business developments
- FY2024 net loss increased by $41.5 million, while operating cash use rose by $57.4 million year over year.
- RP1 remains the lead program. In December 2023, the company reported an investigator-assessed 31.4% overall response rate and 12% complete response rate in the 156-patient anti-PD-1-failed melanoma dataset for RP1 plus nivolumab.
- Following FDA discussions, the company said it planned to submit a BLA for the melanoma cohort in the second half of 2024 and expected topline primary data in the second quarter of 2024. The FDA requested at least six months of follow-up for responding patients and independent central review using RECIST v1.1, in addition to the study’s modified RECIST assessments.
- The FDA requested that the confirmatory Phase 3 IGNYTE-3 trial be underway at BLA submission under the accelerated-approval pathway. The company planned to begin enrollment in the second half of 2024.
- The Phase 2 CERPASS trial in cutaneous squamous cell carcinoma did not meet either primary endpoint. RP1 plus cemiplimab had a 38.1% complete response rate versus 25% for cemiplimab alone (p=0.040), short of the study’s required statistical threshold; overall response rates were 52.5% and 51.4%, respectively (p=0.692). The trial continues to assess duration of response, progression-free survival and overall survival.
- RP1 monotherapy in the ARTACUS transplant-recipient study showed a 34.8% response rate among 23 evaluable patients in the interim dataset; no immune-mediated events or allograft rejection were observed in that dataset. Enrollment continues.
- Portfolio priorities shifted: RP3 development was discontinued for the time being; RP2 development in head-and-neck cancer and colorectal cancer was discontinued, with already enrolled or screening patients continuing treatment. The Roche colorectal collaboration was terminated; the company plans to pursue a second-line HCC study with RP2, with Roche indicating it may supply atezolizumab and bevacizumab but is unlikely to share costs.
Outlook, risks and unusual items
- The company expects continued substantial losses and has no product revenue or committed external funding source. Additional financing may be required; equity financing could dilute shareholders.
- Key execution risks include clinical-trial outcomes and enrollment, regulatory acceptance of data and accelerated approval, manufacturing qualification and supply, and dependence on third-party checkpoint inhibitors and research or clinical service providers.
- The Hercules facility has a $200 million maximum potential principal facility, but further borrowing is subject to conditions. Interest-only payments run through September 2026, with maturity in October 2027. Covenants include cash requirements and, under specified conditions, revenue, market-capitalization or cash tests; a default could accelerate repayment and expose collateral.
- The Framingham manufacturing facility is operational, and comparability work for RP1, RP2 and RP3 is complete; the FDA and some European regulators have approved its material for clinical trials. Commercial readiness, ongoing regulatory compliance and expected cost efficiencies remain execution risks.
- Amgen patent litigation challenges were settled in August 2023. The company agreed to pay low-single-digit royalties on net sales of products that, absent the license, could be found to infringe a valid Amgen patent, on a country- and product-specific basis.
- Management reported effective disclosure controls and internal control over financial reporting as of March 31, 2024. The financial statements received an unqualified audit opinion; the auditor did not provide an opinion on internal control effectiveness. No material legal proceedings were reported.
Important facts for investors to verify
- Whether the anticipated RP1 melanoma data, BLA submission and IGNYTE-3 launch occurred on the stated timelines, and whether FDA requirements or the accelerated-approval pathway changed.
- How final, centrally reviewed RP1 response data compare with the reported investigator-assessed results, including durability and safety.
- What the continuing CERPASS follow-up shows for duration of response, progression-free survival and overall survival despite missed primary endpoints.
- Whether the $420.7 million liquidity balance supports the projected runway given cash burn, clinical commitments, manufacturing costs and potential financing needs.
- Hercules covenant compliance and repayment exposure, including any additional borrowing, required cash levels or trigger events.